115,000 Shares in Global Blood Therapeutics, Inc. (GBT) Acquired by York Capital Management Global Advisors LLC

York Capital Management Global Advisors LLC acquired a new position in Global Blood Therapeutics, Inc. (NASDAQ:GBT) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 115,000 shares of the company’s stock, valued at approximately $4,238,000. York Capital Management Global Advisors LLC owned approximately 0.26% of Global Blood Therapeutics as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the company. Artal Group S.A. increased its position in shares of Global Blood Therapeutics by 146.1% in the fourth quarter. Artal Group S.A. now owns 246,054 shares of the company’s stock worth $3,555,000 after buying an additional 146,054 shares in the last quarter. Oxford Asset Management increased its position in shares of Global Blood Therapeutics by 264.5% in the fourth quarter. Oxford Asset Management now owns 140,845 shares of the company’s stock worth $2,035,000 after buying an additional 102,200 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Global Blood Therapeutics during the fourth quarter worth about $10,462,000. Bank of Montreal Can bought a new position in shares of Global Blood Therapeutics during the first quarter worth about $597,000. Finally, State Street Corp increased its position in shares of Global Blood Therapeutics by 1.4% in the fourth quarter. State Street Corp now owns 289,984 shares of the company’s stock worth $4,174,000 after buying an additional 4,024 shares in the last quarter. Institutional investors own 72.42% of the company’s stock.

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics, Inc. (NASDAQ GBT) traded down 0.37% during trading on Friday, reaching $26.70. 3,552,467 shares of the company’s stock traded hands. The stock’s market capitalization is $1.16 billion. The company has a 50-day moving average of $29.38 and a 200 day moving average of $25.47. Global Blood Therapeutics, Inc. has a 12 month low of $13.35 and a 12 month high of $41.15.

Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings results on Monday, May 1st. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.11. During the same quarter in the prior year, the firm earned ($0.56) earnings per share. On average, equities research analysts expect that Global Blood Therapeutics, Inc. will post ($2.55) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “115,000 Shares in Global Blood Therapeutics, Inc. (GBT) Acquired by York Capital Management Global Advisors LLC” was reported by sleekmoney and is the property of of sleekmoney. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://sleekmoney.com/115000-shares-in-global-blood-therapeutics-inc-gbt-acquired-by-york-capital-management-global-advisors-llc/1916462.html.

A number of brokerages have recently issued reports on GBT. ValuEngine upgraded shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 10th. Roth Capital set a $47.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a report on Saturday, February 18th. SunTrust Banks, Inc. began coverage on shares of Global Blood Therapeutics in a report on Monday, April 17th. They issued a “buy” rating and a $56.00 price target for the company. Janney Montgomery Scott began coverage on shares of Global Blood Therapeutics in a report on Monday, May 1st. They issued a “buy” rating and a $37.00 price target for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $73.00 price target on shares of Global Blood Therapeutics in a report on Monday, March 20th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $50.37.

In other Global Blood Therapeutics news, major shareholder Robert I. Tepper sold 31,225 shares of the business’s stock in a transaction dated Thursday, April 6th. The shares were sold at an average price of $33.23, for a total value of $1,037,606.75. Following the sale, the insider now directly owns 229,773 shares in the company, valued at $7,635,356.79. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.10% of the stock is currently owned by insiders.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT).

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/115000-shares-in-global-blood-therapeutics-inc-gbt-acquired-by-york-capital-management-global-advisors-llc/1916462.html

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *